BACKGROUND: Alzheimer disease (AD) is the most frequent cause of dementia. Even though the incidence of AD in the African American population is similar to or higher than that in persons of European descent, AD in African Americans is understudied. Identification of genetic risk factors in African Americans is essential for understanding the etiology of AD. OBJECTIVE: To determine the effect of apolipoprotein E (APOE) genotype on the risk of AD in elderly African Americans. DESIGN: Population-based longitudinal study of AD. SETTING: Indianapolis, Ind. PARTICIPANTS: African Americans 65 years and older. MAIN OUTCOME MEASURES: APOE genotype and diagnosis of AD. RESULTS: The APOE genotype was determined in 1822 samples. Of these, 690 were clinically evaluated: 318 were normal, and 162 had a diagnosis of AD. The presence of APOE epsilon4 was significantly associated with increased risk of AD (epsilon3/epsilon4: OR, 2.32; 95% confidence interval [CI], 1.41-3.82; and epsilon4/epsilon4: OR, 7.19; 95% CI, 3.00-17.29, compared with the epsilon3/epsilon3 genotype). There was also a significant protective effect with APOE epsilon2 (epsilon2/epsilon2 and epsilon2/epsilon3: OR, 0.42; 95% CI, 0.20-0.89). CONCLUSIONS: These findings are in marked contrast to the lack of association between APOE and AD in the Ibadan, Nigeria, sample of this project. These results suggest that other genetic factors and different environmental influences may play a role in the risk for AD in individuals of African ancestry.
BACKGROUND:Alzheimer disease (AD) is the most frequent cause of dementia. Even though the incidence of AD in the African American population is similar to or higher than that in persons of European descent, AD in African Americans is understudied. Identification of genetic risk factors in African Americans is essential for understanding the etiology of AD. OBJECTIVE: To determine the effect of apolipoprotein E (APOE) genotype on the risk of AD in elderly African Americans. DESIGN: Population-based longitudinal study of AD. SETTING: Indianapolis, Ind. PARTICIPANTS: African Americans 65 years and older. MAIN OUTCOME MEASURES: APOE genotype and diagnosis of AD. RESULTS: The APOE genotype was determined in 1822 samples. Of these, 690 were clinically evaluated: 318 were normal, and 162 had a diagnosis of AD. The presence of APOE epsilon4 was significantly associated with increased risk of AD (epsilon3/epsilon4: OR, 2.32; 95% confidence interval [CI], 1.41-3.82; and epsilon4/epsilon4: OR, 7.19; 95% CI, 3.00-17.29, compared with the epsilon3/epsilon3 genotype). There was also a significant protective effect with APOE epsilon2 (epsilon2/epsilon2 and epsilon2/epsilon3: OR, 0.42; 95% CI, 0.20-0.89). CONCLUSIONS: These findings are in marked contrast to the lack of association between APOE and AD in the Ibadan, Nigeria, sample of this project. These results suggest that other genetic factors and different environmental influences may play a role in the risk for AD in individuals of African ancestry.
Authors: M X Tang; P Cross; H Andrews; D M Jacobs; S Small; K Bell; C Merchant; R Lantigua; R Costa; Y Stern; R Mayeux Journal: Neurology Date: 2001-01-09 Impact factor: 9.910
Authors: Robert C Green; L Adrienne Cupples; Rodney Go; Kelly S Benke; Timi Edeki; Patrick A Griffith; Mary Williams; Yvonne Hipps; Neill Graff-Radford; David Bachman; Lindsay A Farrer Journal: JAMA Date: 2002-01-16 Impact factor: 56.272
Authors: O S Morgan; D A Eldemire; C H Thesiger; J Luseko; A Sahota; S Gao; K S Hall; H C Hendrie Journal: Ann Neurol Date: 1998-04 Impact factor: 10.422
Authors: B J Gurland; D E Wilder; R Lantigua; Y Stern; J Chen; E H Killeffer; R Mayeux Journal: Int J Geriatr Psychiatry Date: 1999-06 Impact factor: 3.485
Authors: Oye Gureje; Adesola Ogunniyi; Olusegun Baiyewu; Brandon Price; Frederick W Unverzagt; Rebecca M Evans; Valerie Smith-Gamble; Kathleen A Lane; Sujuan Gao; Kathleen S Hall; Hugh C Hendrie; Jill R Murrell Journal: Ann Neurol Date: 2006-01 Impact factor: 10.422
Authors: Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider Journal: Arch Neurol Date: 2003-02
Authors: Neill R Graff-Radford; Robert C Green; Rodney C P Go; Michael L Hutton; Timi Edeki; David Bachman; Jennifer L Adamson; Patrick Griffith; Floyd B Willis; Mary Williams; Yvonne Hipps; Jonathan L Haines; L Adrienne Cupples; Lindsay A Farrer Journal: Arch Neurol Date: 2002-04
Authors: G G Fillenbaum; A Heyman; M S Huber; M A Woodbury; J Leiss; K E Schmader; A Bohannon; B Trapp-Moen Journal: J Clin Epidemiol Date: 1998-07 Impact factor: 6.437
Authors: Mark T W Ebbert; Perry G Ridge; Andrew R Wilson; Aaron R Sharp; Matthew Bailey; Maria C Norton; JoAnn T Tschanz; Ronald G Munger; Christopher D Corcoran; John S K Kauwe Journal: Biol Psychiatry Date: 2013-08-13 Impact factor: 13.382
Authors: Hugh C Hendrie; Jill Murrell; Olusegun Baiyewu; Kathleen A Lane; Christianna Purnell; Adesola Ogunniyi; Frederick W Unverzagt; Kathleen Hall; Christopher M Callahan; Andrew J Saykin; Oye Gureje; Ann Hake; Tatiana Foroud; Sujuan Gao Journal: Int Psychogeriatr Date: 2014-02-24 Impact factor: 3.878
Authors: Kunal Thaker; Marilyn Chwa; Shari R Atilano; Pinar Coskun; Javier Cáceres-Del-Carpio; Nitin Udar; David S Boyer; S Michal Jazwinski; Michael V Miceli; Anthony B Nesburn; Baruch D Kuppermann; M Cristina Kenney Journal: Neurobiol Dis Date: 2016-04-22 Impact factor: 5.996
Authors: Amy R Borenstein; James A Mortimer; Gerard D Schellenberg; Charles DeCarli; Cathleen Copenhaver; Douglas Galasko; David P Salmon; Ronald Petersen Journal: Am J Alzheimers Dis Other Demen Date: 2010-02-08 Impact factor: 2.035
Authors: Neill R Graff-Radford; Lilah M Besser; Julia E Crook; Walter A Kukull; Dennis W Dickson Journal: Alzheimers Dement Date: 2016-04-16 Impact factor: 21.566